0001564590-22-037666 | 10-Q | XBRL Viewer

Print Document View Excel Document

Accrued expenses and other current liabilities - Schedule of Other Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Payroll and related costs	$ 8,460	$ 13,764
Rebates	16,854	11,010
Sales returns and coupons	3,434	2,422
Selling and marketing	3,475	2,850
Research and development expenses	1,826	1,995
Wholesale distributor fees	4,520	3,614
Professional fees	739	2,571
Operating lease liabilities	$ 1,383	$ 1,361
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Income taxes payable	$ 290
Other accrued expenses and current liabilities	2,587	$ 4,717
Accrued expenses and other current liabilities	$ 43,568	$ 44,304

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Less: deferred financing fees	$ 830	$ 11,731
Debt, net	93,602	188,269
Financing Agreement [Member]
Debt Instrument [Line Items]
Financing Agreement	$ 94,432	$ 200,000

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Rubric Capital Management LP Subscription Agreements (Sale of mandatory redeemable preferred stock and common stock) - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended				9 Months Ended
	Sep. 30, 2022	Jul. 29, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Aggregate purchase price			$ 2,454	$ 31,819	$ 163	$ 150,899
Preferred Stock, Shares Authorized	10,000,000		10,000,000				10,000,000	10,000,000
Change of Control Transactions [Member]
Class Of Stock [Line Items]
Preferred stock, redemption price per share	$ 1,333		$ 1,333				$ 1,333
Bankruptcy Proceeding [Member]
Class Of Stock [Line Items]
Preferred stock, redemption price per share	1,333		1,333				1,333
Extension Terms [Member]
Class Of Stock [Line Items]
Preferred stock, redemption price per share	1,333		$ 1,333				1,333
Common Stock [Member]
Class Of Stock [Line Items]
Shares issued and sold			565,000	575,000	3,000	1,857,000
Aggregate purchase price				$ 1		$ 2
Subscription Agreement [Member] \| Rubric Capital Management LP [Member] \| Private Placement Offering [Member]
Class Of Stock [Line Items]
Preferred stock liquidation preference value per share	$ 1,333		$ 1,333				$ 1,333
Preferred stock, dividend rate, percentage							25.00%
Subscription Agreement [Member] \| Common Stock [Member] \| Rubric Capital Management LP [Member] \| Private Placement Offering [Member]
Class Of Stock [Line Items]
Shares issued and sold		565,000
Purchase price per share		$ 4.72
Aggregate purchase price		$ 2,700
Number of shares for make-whole payment under financing agreement	263,666
Series A Preferred Stock [Member] \| Subscription Agreement [Member] \| Rubric Capital Management LP [Member] \| Private Placement Offering [Member]
Class Of Stock [Line Items]
Shares issued and sold	7,000	15,000
Purchase price per share		$ 822.21
Aggregate purchase price	$ 7,000	$ 12,300
Aggregate gross proceeds	$ 7,000	$ 15,000
Preferred Stock, Shares Authorized	30,000		30,000				30,000
Preferred stock, shares outstanding	22,000		22,000				22,000
Preferred stock liquidation preference value per share	$ 1,333		$ 1,333				$ 1,333

Licensed rights and other intangible assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 0.1	$ 0.1	$ 0.4	$ 0.2
License rights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 0.8	$ 0.8	$ 2.3	$ 2.3

Business concentrations - Summary of Vendors with Product Purchases (Details) - Product purchases [Member] - Vendor Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Catalent [Member]
Disclosure Of Vendors With Product Purchases And Accounts Payable For The Periods [Line Items]
Concentration Risk, Percentage	23.00%	27.00%
Vendor A [Member]
Disclosure Of Vendors With Product Purchases And Accounts Payable For The Periods [Line Items]
Concentration Risk, Percentage	49.00%	41.00%
Vendor B [Member]
Disclosure Of Vendors With Product Purchases And Accounts Payable For The Periods [Line Items]
Concentration Risk, Percentage	25.00%	30.00%

Debt - Summary of Interest Expense and Other Financing Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Interest expense	$ 2,251	$ 5,391	$ 10,888	$ 17,175
Interest prepayment fees		650		4,008
Financing fees amortization	2,582	1,477	20,053	4,158
Interest expense and other financing costs	$ 4,833	$ 7,518	$ 30,941	$ 25,341

Accrued expenses and other current liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Payables And Accruals [Abstract]

Schedule of Other Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Payroll and related costs	$	8,460	$	13,764
Rebates		16,854		11,010
Sales returns and coupons		3,434		2,422
Selling and marketing		3,475		2,850
Research and development expenses		1,826		1,995
Wholesale distributor fees		4,520		3,614
Professional fees		739		2,571
Operating lease liabilities		1,383		1,361
Income taxes payable		290		—
Other accrued expenses and current liabilities		2,587		4,717
Accrued expenses and other current liabilities	$	43,568	$	44,304

Fixed assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Depreciation	$ 0.2	$ 0.2	$ 0.5	$ 0.6

CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	9 Months Ended
CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Statement Of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss \| $	$ 1,621	$ 1,334
Preferred Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	22,000	22,000
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001	$ 0.001
Common Stock, Shares Authorized	12,000,000	12,000,000
Common Stock, Shares, Issued	9,467,000	8,598,000
Common Stock, Shares, Outstanding	9,467,000	8,598,000
Reverse stock split, conversion ratio	0.02
Reverse stock split, description	50-for-1 reverse stock split

Business concentrations

9 Months Ended

Sep. 30, 2022

Risks And Uncertainties [Abstract]

Business concentrations

15.	Business concentrations

We sell our products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers.

Customers with product revenue equal to or greater than 10% of our total revenue for the periods indicated were as follows:

	Nine Months Ended September 30,
	2022	2021
Customer A	*	10%
Customer B	18%	16%
Customer C	17%	18%
Customer E	*	12%
Customer F	16%	*
* Less than 10% of total product revenue

Customers that accounted for 10% or greater of our accounts receivable as of the periods indicated were as follows:

	September 30, 2022	December 31, 2021
Customer B	27%	21%
Customer C	19%	35%
Customer D	10%	11%
Customer G	20%	*
* Balance was less than 10% of accounts receivable, gross

We rely on third parties for the manufacture and supply of our products, as well as third-party logistics providers. In instances where these parties fail to perform their obligations, we may be unable to find alternative suppliers or satisfactorily deliver our products to our customers on time, if at all.

Vendors with product purchases equal to or greater than 10% of our total purchases for the periods indicated were as follows:

	Nine Months Ended September 30,
	2022	2021
Catalent	23%	27%
Vendor A	49%	41%
Vendor B	25%	30%
* Less than 10% of total product purchases

Vendors that accounted for 10% or greater of our accounts payable as of the periods indicated were as follows:

	September 30, 2022	December 31, 2021
Vendor E	*	19%
Vendor F	32%	20%
* Balance was less than 10% of total accounts payable

Prepaid and other current assets - Schedule of prepaid and other current assets consisted of the following (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense And Other Assets Current [Abstract]
Insurance	$ 2,370	$ 2,731
Paragraph IV legal proceeding costs	2,334	2,304
Other	5,586	5,513
Prepaid and other current assets	$ 10,290	$ 10,548

Earnings (loss) per common share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Summary of computation of basic and diluted earnings (loss) per common share

The following table sets forth the computation of basic and diluted earnings (loss) per common share (each adjusted to account for the 50-for-1 reverse stock split) for the periods presented (in thousands, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022		2021
Numerator:
Net income (loss)	$	(28,965	)	$	(47,420	)	$	34,295	$	(129,455	)
Denominator:
Weighted average common shares for basic loss per common share		9,261			8,444			8,877		7,762
Effect of dilutive securities		—			—			328		—
Weighted average common shares for diluted loss per common share		9,261			8,444			9,205		7,762
Earnings (loss) per common share, basic	$	(3.13	)	$	(5.62	)	$	3.86	$	(16.68	)
Earnings (loss) per common share, diluted	$	(3.13	)	$	(5.62	)	$	3.73	$	(16.68	)

Schedule of antidilutive securities excluded from computation of earnings per share

The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per common share during the respective three months ended September 30, 2022, and three and nine months ended September 31, 2021 (in thousands):

	As of September 30,
	2022		2021
Stock options		197		369
RSUs		301		323
PSUs		100		194
Warrants		411		103
		1,009		989

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Schedule of Performance Stock Units (Parenthetical) (Details) - Performance Shares Unit [Member]	Sep. 30, 2022 shares
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares will vest upon the achievement of performance goals	0
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares will vest upon the achievement of performance goals	165,548

Mandatory Redeemable Preferred Stock and Stockholders' Deficit

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Mandatory Redeemable Preferred Stock and Stockholders' Deficit

10.	Mandatory Redeemable Preferred Stock and Stockholders’ Deficit

Rubric Capital Management LP Subscription Agreements (Sale of Mandatory Redeemable Preferred Stock and Common Stock)

On July 29, 2022, we entered into a Subscription Agreement with the Preferred Stock Investor, pursuant to which we issued and sold, in a private placement offering, (i) 15,000 shares of the Company’s newly issued Preferred Stock, for a purchase price per share of Preferred Stock equal to $822.21 and an aggregate purchase price of $12.3 million, and (ii) 565,000 shares of the Company’s Common Stock, for a purchase price per share of Common Stock equal to $4.72 and an aggregate purchase price of $2.7 million. This offering closed on July 29, 2022, and we received aggregate gross proceeds of $15.0 million, before expenses.

On September 30, 2022, we entered into a Subscription Agreement with the Preferred Stock Investor, pursuant to which we issued and sold, in a private placement offering, 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of the Company’s Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the Preferred Stock Maturity Date or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment. This offering closed on September 30, 2022, and we received gross proceeds of $7.0 million, before expenses. Based on the structure of the make-whole payment, it is recorded as make-whole payment derivative liability in the consolidated balance sheets and the carrying amounts are marked to market based on our Common Stock’s closing price at measurement date, which is considered Level 1 under the fair value hierarchy. As of September 30, 2022, we had 30,000 and 22,000 shares of Series A Preferred Stock authorized and outstanding, respectively, at the liquidation preference of $1,333 per share.

The Preferred Stock is not convertible into Common Stock and ranks senior to Common Stock, with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, the Preferred Stock has a liquidation preference equal to $1,333 per share. The Preferred Stock will not have any voting rights other than as required by applicable law. The holders of Preferred Stock are entitled to dividends equal to 25% of cash dividends actually paid, if any, on shares of Common Stock, paid pro rata on the outstanding shares of Preferred Stock. If the Company undergoes certain change of control transactions, the holders of Preferred Stock may require the Company to redeem their shares of Preferred Stock at a redemption price per share of Preferred Stock, payable in cash, equal to the liquidation preference of $1,333 per share of Preferred Stock. We also have the option to redeem the shares of Preferred Stock on such terms if the Company undergoes certain change of control transactions. Each holder of the Preferred Stock has the right to cause the Company to redeem all, but not less than all, of their shares of the Preferred Stock upon the occurrence of certain events, including, without limitation, the Company’s failure to comply with any covenants under the Certificate of Designation, Preferences and Rights of Series A Preferred Stock (the “Certificate of Designation”) filed with the Secretary of State of the State of Nevada or if the Company commences a bankruptcy proceeding, subject to certain conditions. Under such circumstances, the Company is required to redeem all, but not less than all, of the holder’s outstanding shares of Preferred Stock at a redemption price per share of Preferred Stock, payable in cash, equal to the liquidation preference of $1,333 per share. The Preferred Stock matures on December 31, 2022, subject to certain extension terms, as set forth in the Certificate of Designation, and the Company is required to redeem the shares on such date at a redemption price per share of Preferred Stock, payable in cash, equal to the liquidation preference of $1,333 per share. Since the Preferred Stock is mandatorily redeemable on December 31, 2022, the Company has classified the Preferred Stock as a current liability in the consolidated balance sheets. In addition, the Company is accreting the Preferred Stock from its fair value on the date of issuance to its redemption value using the effective interest rate method.

Warrants

As of September 30, 2022, the following table summarizes the status of our outstanding and exercisable warrants and related transactions (each adjusted to account for the 50-for-1 reverse stock split) since December 31, 2021 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Outstanding									Exercisable
	Warrants			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2022		103		$	76.19	$	—		8.3		103	$	76.19	$	—		8.3
Granted		311			0.20
Expired		(3	)		341.50
As of September 30, 2022		411		$	17.08	$	2,055		9.3		286	$	24.54	$	2,055		9.1

The above table includes an aggregate of Lenders Warrants to purchase 310,000 shares of our Common Stock with an exercise price of $0.01 per warrant that are classified as Lender Warrants derivative liability. See Note 8, Debt, for additional information.

Share-based compensation payment plans

As of September 30, 2022, 598,223 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). If we assume the maximum achievement of performance goals for PSUs, then 663,731 shares of common stock will be subject to outstanding awards under our share-based payment award plans and inducement grants. As of September 30, 2022, 242,015 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.

The following table summarizes the status of our outstanding and exercisable options and related transactions (each adjusted to account for the 50-for-1 reverse stock split) since December 31, 2021 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Outstanding									Exercisable
	Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Options Awards		Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2022		353		$	225.98	$	-		3.8		336	$	230.93	$	-		3.6
Cancelled/Forfeited		(1	)		1,885.39
Expired		(155	)		238.45
As of September 30, 2022		197		$	216.65	$	-		3.5		192	$	219.65	$	-		3.4

The following table summarizes the status of our RSUs and related transactions (each adjusted to account for the 50-for-1 reverse stock split) since December 31, 2021 (in thousands, except weighted average grant date fair value):

	Outstanding							Vested and not settled
	RSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value		RSUs		Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2022		272		$	58.93	$	4,891		31	$	105.28	$	566
Granted		170			16.05
Vested and settled		(106	)		69.42		1,180
Cancelled/Forfeited		(35	)		54.91
As of September 30, 2022		301		$	31.50	$	1,998		104	$	38.58	$	692

The following table summarizes the status of our PSUs and related transactions (each adjusted to account for the 50-for-1 reverse stock split) since December 31, 2021 (in thousands, except weighted average grant date fair value):

	Outstanding								Vested and not settled
	PSUs				Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value		PSUs		Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2022		164			$	51.50	$	2,953		39	$	58.81	$	709
Granted		63				34.50
Vested and settled		(52	)			58.26		695
Cancelled/Forfeited		(75	)			44.82
As of September 30, 2022		100		⁽¹⁾	$	42.32	$	664		43	$	—	$	282

⁽¹⁾	^{The number of PSUs represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and 165,548 depending on the Company’s achievement of certain performance goals.}

Share-based payment compensation cost

Share-based payment compensation cost for PSUs is based on our current assessment of the most likely probability of the Company’s achievement of certain performance goals. In connection with previously granted options, RSUs and PSUs, and shares of common stock issuable under the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan (“ESPP”), we recorded share-based payment compensation costs of $4.3 million and $7.3 million for the three months ended September 30, 2022 and 2021, respectively, and $8.6 million and $12.8 million for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022, we had $6.1 million of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under the ESPP, which may be adjusted if certain performance targets are achieved and for future changes in forfeitures and is included as additional paid-in capital in the accompanying consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses. The unrecognized compensation cost as of September 30, 2022 is expected to be recognized as share-based payment award compensation over a weighted average period of 1.8 years as follows (in thousands):

Year Ending December 31,
2022 (3 months)	$	1,098
2023		3,255
2024		1,556
2025		157
	$	6,066

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Business, basis of presentation, new accounting standards and summary of significant accounting policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Business, basis of presentation, new accounting standards and summary of significant accounting policies

1.	Business, basis of presentation, new accounting standards and summary of significant accounting policies

General

TherapeuticsMD, Inc., a Nevada corporation (the “Company”) and its consolidated subsidiaries are referred to collectively in this Quarterly Report on Form 10-Q (“10-Q Report”) as “TherapeuticsMD,” “we,” “our” and “us.” This 10-Q Report includes our trademarks, trade names and service marks, such as TherapeuticsMD^®, vitaMedMD^®, BocaGreenMD^®, IMVEXXY^®, BIJUVA^® and ANNOVERA^®, which are protected under applicable intellectual property laws and are the property of, or licensed to, the Company. Solely for convenience, trademarks, trade names and service marks referred to in this 10-Q Report may appear without the ^®, ^TM or ^SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.

We are a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women’s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products.

vitaCare Divestiture

On April 14, 2022, we completed the divestiture of vitaCare Prescription Services, Inc. (“vitaCare”) with the sale of all of vitaCare’s issued and outstanding capital stock (the “vitaCare Divestiture”). We received net proceeds of $142.6 million, net of transaction costs of $7.2 million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary holdbacks as provided in the stock purchase agreement (the “Purchase Agreement”), which is recorded as restricted cash in the consolidated balance sheets. The restricted cash is held by an escrow agent and will be released to us in April 2023 upon a joint written direction from the buyer and us being delivered to the escrow agent to disburse to us an amount equal to the amount of escrow funds less any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement. Any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement shall be retained by the escrow agent until each such claim subject thereto is resolved. Additionally, we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare’s financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement. We will record the contingent consideration at the settlement amount when the consideration is realized or realizable.

The Purchase Agreement contains customary representations and warranties, covenants, and indemnities of the parties thereto. In addition, upon closing of the vitaCare Divestiture, (i) we entered into a long-term services agreement with vitaCare to continue utilization of the vitaCare platform with respect to our products, and (ii) we entered into a transition services agreement with vitaCare for us to provide certain transition services to vitaCare for up to 12 months following the closing. Under the long-term services agreement, we are required to pay to vitaCare a minimum service fee for each respective annual contract year. Our estimated minimum service fee commitments for vitaCare are as follows: $2.0 million for the period from October 1, 2022 to December 31, 2022, $10.7 million for 2023, $13.4 million for 2024, $15.4 million for 2025, $16.2 million for 2026, and $5.5 million for the period from January 1, 2027 to April 14, 2027.

COVID-19

With multiple variant strains of the SARS-Cov-2 virus and the COVID-19 disease that it causes (collectively, “COVID-19”) still circulating, we continue to be subject to risks and uncertainties in connection with the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. The ultimate global recovery from the pandemic will be dependent on, among other things, actions taken by governments and businesses to contain and combat the virus, including any variant strains, the speed and effectiveness of vaccine production and global distribution, as well as how quickly, and to what extent, normal economic and operating conditions can resume on a sustainable basis globally.

Since the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. We have also partnered with independent community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause which provide patients real-time access to both diagnosis and treatment. We continue to support prescribers’ needs with samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity plans and infrastructure in place that allows for live virtual e-detailing of our products.

As part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses and implemented cost saving measures, which included negotiating lower fees or suspending services from third-party vendors; implementing a company-wide hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event expenses. In addition, we implemented a significant cost savings initiative that was designed to reduce our annual operating costs in 2022, and we reduced the operating costs of the vitaCare business with the completion of the vitaCare Divestiture on April 14, 2022. See above for additional information regarding the vitaCare Divestiture.

The full impact of the COVID-19 pandemic continues to evolve. As of the date of issuance of these consolidated financial statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity, or results of operations remains uncertain. We are continuing to assess the effect of the COVID-19 pandemic on our operations by monitoring the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future.

While we currently believe that our COVID-19 contingency plan has the ability to mitigate many of the negative effects of the COVID-19 pandemic on our business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, the duration of “social distancing” orders, the ability of our sales force to access healthcare providers to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which remain uncertain. Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that we may face.

Going concern

We incurred a loss from operations of $65.8 million and interest expense and other financing costs of $30.9 million during the nine months ended September 30, 2022, and as of that date, our current liabilities exceeded our current assets by $86.6 million and our total liabilities exceeded our total assets by $48.3 million. We will need to raise additional capital to repay the entire principal balance of the Financing Agreement, dated as of April 24, 2019, as amended (the “Financing Agreement”), with Sixth Street Specialty Lending, Inc., as administrative agent (the “Administrative Agent” or “Sixth Street”), various lenders from time to time party thereto (the “Lenders”), and certain of our subsidiaries party thereto from time to time as guarantors, and to provide additional liquidity to fund our losses until our operations become cash flow positive.

On July 29, 2022, we closed on a private placement offering with Rubric Capital Management LP (the “Preferred Stock Investor”), pursuant to which we issued and sold (i) 15,000 shares of the Company’s newly-designated Series A Preferred Stock, par value $0.001 per share (“Preferred Stock”) and (ii) 565,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and we received aggregate gross proceeds of $15.0 million, before expenses. On September 30, 2022, we closed on an additional private placement offering with the Preferred Stock Investor, pursuant to which we issued and sold 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the maturity date of the Preferred Stock of December 31, 2022, which shall be automatically extended, on a day-for-day basis, to the extent the maturity date under the Financing Agreement is extended, but by no more than a total of 60 days without the consent of the holders representing at least 66 2/3% of the outstanding shares of Preferred Stock (the “Preferred Stock Maturity Date”) or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment. See Note 10, Mandatory Redeemable Preferred Stock and Stockholders’ Deficit for additional information regarding the financing with the Preferred Stock Investor.

In connection with the closing of the private placement offering with the Preferred Stock Investor on September 30, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on September 30, 2022, we issued warrants (“Lender Warrants”) to the Lenders to purchase an aggregate of 125,000 shares of Common Stock and the maturity date of the Financing Agreement was extended to October 31, 2022. The Lender Warrants have an exercise price of $0.01 per share of Common Stock, subject to certain adjustment as provided therein, and an expiration date of September 30, 2032. The Lender Warrants may also be exercised via cashless exercise pursuant to the terms thereof.

On October 28, 2022, we closed on an additional private placement offering with the Preferred Stock Investor, pursuant to which we issued and sold 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the Preferred Stock Maturity Date or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment.

In connection with the closing of the private placement offering with the Preferred Stock Investor on October 28, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on October 28, 2022, we issued Lender Warrants to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement and the maturity date of the Financing Agreement was extended to November 30, 2022. See Note 16, Subsequent Events for additional information regarding amendments to the Financing Agreement.

To address our capital needs, we are pursuing various equity and debt refinancing and other strategic alternatives, including the possibility that we will file for Chapter 11 protection if our equity and debt refinancing or other strategic alternatives fail prior to the maturity date of our Financing Agreement. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. Along with considering additional financings and other strategic alternatives, we have reviewed numerous potential scenarios in connection with steps that we may take to reduce our operating expenses.

If we are unsuccessful with future financings, if the successful commercialization of ANNOVERA, IMVEXXY, or BIJUVA is delayed, or if the continued impact of the COVID-19 pandemic or issues in our supply chains related to our third-party contract manufacturers on our business is worse than we anticipate, our existing cash reserves would be insufficient to repay the entire principal balance of the Financing Agreement or satisfy our liquidity needs. The presence of these projected factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the issuance of these financial statements.

The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Common stock reverse stock split

On May 6, 2022, we completed a reverse stock split of our Common Stock. As a result, outstanding shares of our Common Stock were split at a ratio of 50-for-1 (the “Reverse Stock Split”) with any fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized shares of Common Stock was also correspondingly reduced from 600.0 million shares to 12.0 million shares to give effect to the Reverse Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (“RSUs”) and performance stock units (“PSUs”) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders was not required for our Board of Directors (the “Board”) to effectuate the Reverse Stock Split.

In this 10-Q Report, all historical number of shares of Common Stock and per share data have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.

A.	Basis of presentation

We prepared the consolidated financial statements included in this 10-Q Report following the requirements of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. (“U.S. GAAP”) for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our 2021 Annual Report on Form 10-K ("2021 10-K Report").

Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair statement of the financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in this 10-Q Report should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 10-K Report. Certain amounts in the consolidated financial statements and accompanying notes may not add due to rounding, and all percentages have been calculated using unrounded amounts.

B.	New accounting standards

Adoption of new accounting standards

New accounting standards or accounting standards updates were assessed and determined to be either not applicable or did not have a material impact on the Company’s consolidated financial statements or processes.

Accounting standards issued but not yet adopted

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and Scope. In March 2020 and January 2021, Accounting Standards Update (“ASU”) 2020-04 and ASU 2021-01 were issued, respectively. These ASUs provide optional guidance for a limited period of time to ease potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank Offered Rate (LIBOR). These ASUs include practical expedients for contract modifications due to reference rate reform. Generally, contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment of a previous accounting determination at the modification date. These ASUs were effective upon issuance and may be applied prospectively to contract modifications made or evaluated on or before December 31, 2022. Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.

Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements or processes.

C.	Estimates and assumptions

The preparation of consolidated financial statements in conformity to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.

D.	Significant accounting policies

The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1, Business, basis of presentation, new accounting standards and summary of significant accounting policies of the accompanying notes to the consolidated financial statements included in our 2021 10-K Report, and in the section below.

Restricted Cash

Restricted cash is comprised of escrowed funds deposited with a bank relating to the vitaCare Divestiture.

E.	Reclassification of prior year presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported consolidated balance sheets and consolidated statements of cash flows. An adjustment has been made to the consolidated statements of operations for the three and nine months ended September 30, 2021 to reclassify vitaCare service revenue.

Commitments and contingencies

9 Months Ended

Sep. 30, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and contingencies

9.	Commitments and contingencies

Minimum purchase commitments

We have manufacturing and supply agreements whereby we are required to purchase from Catalent, Inc. (“Catalent”) a minimum number of units of BIJUVA and IMVEXXY softgels during each respective annual contract year. The annual contract period for BIJUVA and IMVEXXY ends each April and July, respectively. If the minimum order quantities of BIJUVA or IMVEXXY are not met, we are required to pay a minimum commitment fee equal to 50% or 60%, respectively, of the difference between the total amount we would have paid if the minimum requirement had been fulfilled and the total amount of purchases of BIJUVA or IMVEXXY during each product’s respective contract year. Additionally, with another third-party manufacturer, we have a manufacturing and supply agreement, renewable annually, whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year. The annual contract period for ANNOVERA ends each August. If the minimum order quantities of ANNOVERA are not met, we are required to pay a minimum commitment fee equal to the difference between the total amount we would have paid if the minimum requirement had been fulfilled and the total amount of purchases of ANNOVERA during the contract year.

Furthermore, in connection with the vitaCare Divestiture, we entered into a long-term services agreement with vitaCare to continue utilization of the vitaCare platform with respect to our products. Under the long-term services agreement, we are required to pay to vitaCare a minimum service fee for each respective annual contract year. The annual contract period for vitaCare services ends each April.

For each of the three annual contract years ending in 2022 for BIJUVA, IMVEXXY and ANNOVERA, we have met our minimum purchase number of units in all material respects. For annual contract years ending in 2023 and thereafter for BIJUVA, IMVEXXY, ANNOVERA, and vitaCare Services, we will continue to evaluate whether we will be able to meet each annual contract year’s respective minimum purchase commitment and will record a liability for estimated minimum commitment fees if we believe that we will not be able to reasonably meet the minimum purchase commitment. We believe that minimum commitment fees that we may pay in 2022 and 2023, if any, will not have a material impact to our financial position and operating results.

Legal proceedings

In February 2020, we received a Paragraph IV certification notice letter (the “IMVEXXY Notice Letter”) regarding an Abbreviated New Drug Application (“ANDA”) submitted to the FDA by Teva Pharmaceuticals USA, Inc. (“Teva”). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY (the “IMVEXXY Patents”) are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021, the District Court made available a public version of the order following the parties’ agreement to a consent motion to redact information Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. As of September 30, 2022, for the IMVEXXY Paragraph IV legal proceeding, we have incurred and recorded legal costs amounting to $2.3 million in prepaid expenses and other current assets since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding, the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in this legal proceeding, then the related capitalized legal costs for this legal preceding and any unamortized IMVEXXY patent costs that were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding.

From time to time, we are involved in other litigations and proceedings in the ordinary course of business. We are currently not involved in any other litigations and proceedings that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.

Employment agreements

On September 6, 2022, our Board appointed our current interim co-chief executive officers. The separation of our former chief executive officer (“CEO”) from the Company was a termination without “Good Cause,” as defined in his employment agreement. Accordingly, our former CEO received the separation benefits provided therein, and we recorded executive officer severance expenses of $4.8 million, of which $3.2 million was related to share-based compensation recorded in connection with accelerated vesting of certain share-based payment awards for the former CEO. In connection with our former CEO’s separation from the Company, he ceased to serve as a member of our Board.

Fixed assets (Tables)

9 Months Ended

Sep. 30, 2022

Property Plant And Equipment [Abstract]

Summary of Fixed Assets, Net

Our fixed assets, net consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Furniture and fixtures	$	1,304	$	1,407
Computer and office equipment		1,803		1,855
Computer software		375		375
Leasehold improvements		65		80
Fixed assets		3,547		3,717
Less: accumulated depreciation and amortization		2,996		2,518
Fixed assets, net	$	551	$	1,199

Mandatory Redeemable Preferred Stock and Stockholders' Deficit (Tables)

9 Months Ended

Sep. 30, 2022

Summary of our Outstanding and Exercisable Warrants and Related Transactions

	Outstanding									Exercisable
	Warrants			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2022		103		$	76.19	$	—		8.3		103	$	76.19	$	—		8.3
Granted		311			0.20
Expired		(3	)		341.50
As of September 30, 2022		411		$	17.08	$	2,055		9.3		286	$	24.54	$	2,055		9.1

Summary of Stock Option Activity

	Outstanding									Exercisable
	Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Options Awards		Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2022		353		$	225.98	$	-		3.8		336	$	230.93	$	-		3.6
Cancelled/Forfeited		(1	)		1,885.39
Expired		(155	)		238.45
As of September 30, 2022		197		$	216.65	$	-		3.5		192	$	219.65	$	-		3.4

Summary of Unrecognized Share Based Compensation Cost Expected to be Recognized

The unrecognized compensation cost as of September 30, 2022 is expected to be recognized as share-based payment award compensation over a weighted average period of 1.8 years as follows (in thousands):

Year Ending December 31,
2022 (3 months)	$	1,098
2023		3,255
2024		1,556
2025		157
	$	6,066

Restricted Stock Units [Member]

Schedule of RSUs and PSUs

	Outstanding							Vested and not settled
	RSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value		RSUs		Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2022		272		$	58.93	$	4,891		31	$	105.28	$	566
Granted		170			16.05
Vested and settled		(106	)		69.42		1,180
Cancelled/Forfeited		(35	)		54.91
As of September 30, 2022		301		$	31.50	$	1,998		104	$	38.58	$	692

Performance Shares Unit [Member]

Schedule of RSUs and PSUs

	Outstanding								Vested and not settled
	PSUs				Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value		PSUs		Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2022		164			$	51.50	$	2,953		39	$	58.81	$	709
Granted		63				34.50
Vested and settled		(52	)			58.26		695
Cancelled/Forfeited		(75	)			44.82
As of September 30, 2022		100		⁽¹⁾	$	42.32	$	664		43	$	—	$	282

⁽¹⁾	^{The number of PSUs represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and 165,548 depending on the Company’s achievement of certain performance goals.}

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands		9 Months Ended
	Sep. 06, 2022	Sep. 30, 2022	Sep. 30, 2021
Recorded Unconditional Purchase Obligation [Line Items]
Share-based compensation		$ 8,587	$ 12,779
Executive Officer [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Severance expenses	$ 4,800
Share-based compensation	$ 3,200
Prepaid Expenses and Other Current Assets [Member] \| Paragraph Four Certification Notice Letter [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Legal proceeding costs		$ 2,300
BIJUVA [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Minimum supply commitment fee percentage payable		50.00%
IMVEXXY [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Minimum supply commitment fee percentage payable		60.00%

Subsequent events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Oct. 28, 2022	Jul. 29, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Subsequent Event [Line Items]
Aggregate purchase price			$ 2,454	$ 31,819	$ 163	$ 150,899
Subscription Agreement [Member] \| Private Placement Offering [Member] \| Preferred Stock Investor [Member]
Subsequent Event [Line Items]
Number of shares for make-whole payment under financing agreement		263,666
Subscription Agreement [Member] \| Private Placement Offering [Member] \| Preferred Stock Investor [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares for make-whole payment under financing agreement	263,666
Subscription Agreement [Member] \| Private Placement Offering [Member] \| Preferred Stock Investor [Member] \| Preferred Stock [Member]
Subsequent Event [Line Items]
Shares issued and sold		7,000
Aggregate purchase price		$ 7,000
Subscription Agreement [Member] \| Private Placement Offering [Member] \| Preferred Stock Investor [Member] \| Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued and sold	7,000
Aggregate purchase price	$ 7,000
Aggregate gross proceeds	$ 7,000
Financing Agreement Amendment No 16 [Member]
Subsequent Event [Line Items]
Exercise price of common stock		$ 0.01	$ 0.01
Warrants issued to purchase of common stock		185,000	125,000
Financing Agreement Amendment No 16 [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of common stock	$ 0.01
Warrants issued to purchase of common stock	125,000

Business concentrations - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Customer Concentration Risk [Member] \| Maximum [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Customer Concentration Risk [Member] \| Maximum [Member] \| Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Customer Concentration Risk [Member] \| Minimum [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Customer Concentration Risk [Member] \| Minimum [Member] \| Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Vendor Concentration Risk [Member] \| Maximum [Member] \| Product purchases [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Vendor Concentration Risk [Member] \| Maximum [Member] \| Accounts Payable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Vendor Concentration Risk [Member] \| Minimum [Member] \| Product purchases [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Vendor Concentration Risk [Member] \| Minimum [Member] \| Accounts Payable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Summary of our Outstanding and Exercisable Warrants and Related Transactions (Details) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants, outstanding, beginning balance	103,000
Warrants, outstanding, granted	311,000
Warrants, outstanding, expired	(3,000)
Warrants, outstanding, ending balance	411,000	103,000
Weighted average exercise price, outstanding, beginning balance	$ 76.19
Weighted average exercise price, outstanding, granted	0.20
Weighted average exercise price, outstanding, expired	341.50
Weighted average exercise price, outstanding, ending balance	$ 17.08	$ 76.19
Aggregate intrinsic value, outstanding	$ 2,055
Weighted average remaining contractual life (in years), outstanding	9 years 3 months 18 days	8 years 3 months 18 days
Warrants, exercisable, beginning balance	103,000
Warrants, exercisable, ending balance	286,000	103,000
Weighted average exercise price, exercisable, beginning balance	$ 76.19
Weighted average exercise price, exercisable, ending balance	$ 24.54	$ 76.19
Aggregate intrinsic value, exercisable	$ 2,055
Weighted average remaining contractual life (in years), exercisable	9 years 1 month 6 days	8 years 3 months 18 days

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Share-based Compensation Payment Plans - Additional Information (Details) $ in Millions		3 Months Ended		9 Months Ended
	May 06, 2022	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)
Class Of Stock [Line Items]
Reverse stock split, conversion ratio	0.02			0.02
Reverse stock split, description	outstanding shares of our Common Stock were split at a ratio of 50-for-1			50-for-1 reverse stock split
Share-based payment arrangement, expense \| $		$ 4.3	$ 7.3	$ 8.6	$ 12.8
Total unrecognized share based compensation \| $		$ 6.1		$ 6.1
Share-based compensation over a weighted average period				1 year 9 months 18 days
2019 Stock Incentive Plan [Member]
Class Of Stock [Line Items]
Number of shares common stock available		242,015		242,015
Performance Shares Unit [Member]
Class Of Stock [Line Items]
Number of shares outstanding		598,223		598,223
Maximum number shares to be issued upon performance goals are achieved		663,731		663,731
Options [Member]
Class Of Stock [Line Items]
Reverse stock split, conversion ratio				0.02
Reverse stock split, description				50-for-1 reverse stock split
RSU Outstanding [Member]
Class Of Stock [Line Items]
Reverse stock split, conversion ratio				0.02
Reverse stock split, description				50-for-1 reverse stock split
PSUs Outstanding [Member]
Class Of Stock [Line Items]
Reverse stock split, conversion ratio				0.02
Reverse stock split, description				50-for-1 reverse stock split

Revenue - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
Revenue - Additional Information (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Sales	$ 20,917,000	$ 25,406,000	$ 68,811,000	$ 68,273,000
BIJUVA [Member]
Disaggregation of Revenue [Line Items]
Sales	2,663,000	3,298,000	7,877,000	7,899,000
Theramex License Agreement [Member] \| BIJUVA [Member]
Disaggregation of Revenue [Line Items]
Sales	400,000	700,000	1,400,000	700,000
Knight License Agreement [Member] \| BIJUVA [Member]
Disaggregation of Revenue [Line Items]
Sales	$ 0	$ 0	$ 0	$ 0

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Accounts receivable - Summary Of Accounts Receivable Allowance For Credit Losses (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Receivables [Abstract]
Beginning balance	$ 1,334
Charges to provision for credit losses	542	$ 540
Write-off of uncollectible receivables	(255)
Ending Balance	$ 1,621

Earnings (loss) per common share - Additional Information (Details) shares in Thousands		3 Months Ended		9 Months Ended
	May 06, 2022	Sep. 30, 2022 shares	Sep. 30, 2021 shares	Sep. 30, 2022 shares	Sep. 30, 2021 shares
Earnings Per Share [Line Items]
Reverse stock split, conversion ratio	0.02			0.02
Reverse stock split, description	outstanding shares of our Common Stock were split at a ratio of 50-for-1			50-for-1 reverse stock split
Not potentially dilutive securities, Outstanding PSUs		1,009	989		989
PSUs [Member]
Earnings Per Share [Line Items]
Not potentially dilutive securities, Outstanding PSUs		100	194	58	194

Accrued expenses and other current liabilities - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Payables And Accruals [Abstract]
Advertising costs	$ 4.8	$ 14.6	$ 12.6	$ 34.4

Licensed rights and other intangible assets - Summary of Information about License Rights and Other Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	$ 48,125	$ 47,854
Finite-Lived Intangible Assets, Accumulated Amortization	10,570	7,868
Finite-Lived Intangible Assets, Net	37,555	39,986
License Rights and Intangible Assets, Net, Gross Carrying Amount (Excluding Goodwill)	48,446	48,186
License rights and other intangible assets, net	37,876	40,318
License rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	40,000	40,000
Finite-Lived Intangible Assets, Accumulated Amortization	9,086	6,826
Finite-Lived Intangible Assets, Net	30,914	33,174
Hormone therapy drug patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	6,189	5,834
Finite-Lived Intangible Assets, Accumulated Amortization	1,484	1,042
Finite-Lived Intangible Assets, Net	4,705	4,792
Hormone therapy drug candidate patents - applied and pending [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	1,936	2,020
Finite-Lived Intangible Assets, Net	1,936	2,020
Trademarks/trade name rights [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Gross Carrying Amount and Net	$ 321	$ 332

Earnings (loss) per common share - Summary of computation of basic and diluted earnings (loss) per common share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net income (loss)	$ (28,965)	$ 112,281	$ (49,021)	$ (47,420)	$ (42,652)	$ (39,383)	$ 34,295	$ (129,455)
Denominator:
Weighted average common shares for basic loss per common share	9,261			8,444			8,877	7,762
Effect of dilutive securities	0			0			328	0
Weighted average common shares for diluted loss per common share	9,261			8,444			9,205	7,762
(Loss) earnings per common share, basic	$ (3.13)			$ (5.62)			$ 3.86	$ (16.68)
(Loss) earnings per common share, diluted	$ (3.13)			$ (5.62)			$ 3.73	$ (16.68)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Inventory (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Summary of Inventory

Our inventory consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Raw materials	$	1,946	$	3,042
Work in process		218		1,642
Finished products		4,537		2,938
Inventory	$	6,701	$	7,622

Debt (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Schedule of Debt

Our debt consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Financing Agreement	$	94,432	$	200,000
Less: deferred financing fees		830		11,731
Debt, net	$	93,602	$	188,269

Summary of Interest Expense and Other Financing Costs

Interest expense and other financing costs consisted of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Interest expense	$	2,251	$	5,391	$	10,888	$	17,175
Interest prepayment fees		—		650		—		4,008
Financing fees amortization		2,582		1,477		20,053		4,158
Interest expense and other financing costs	$	4,833	$	7,518	$	30,941	$	25,341

Business concentrations - Summary of Vendors Accounted for 10% or Greater of Accounts Payable (Details) - Vendor Concentration Risk [Member] - Accounts Payable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Vendor E [Member]
Disclosure Of Vendors With Product Purchases And Accounts Payable For The Periods [Line Items]
Concentration Risk, Percentage		19.00%
Vendor F [Member]
Disclosure Of Vendors With Product Purchases And Accounts Payable For The Periods [Line Items]
Concentration Risk, Percentage	32.00%	20.00%

Related parties

9 Months Ended

Sep. 30, 2022

Related Parties

14.	Related parties

A former member of our Board, J. Martin Carroll, who resigned in December 2021, is a member of Catalent’s Board. Accordingly, Catalent ceased to be a related a party to the Company in December 2021. From time to time, we have entered into agreements with Catalent and its affiliates in the normal course of business. From July 2015 to December 2021, agreements with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our Company. For manufacturing activities, Catalent billed us $1.1 million and $2.6 million for the three and nine months ended September 30, 2021. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 9, Commitments and contingencies.

On July 29, 2022 and September 30, 2022, we entered into subscription agreements with Rubric Capital Management L.P. See Note 10, Mandatory Redeemable Preferred Stock and Stockholders’ Deficit for additional information.

On August 23, 2022, we appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board as a result of the Board’s increase in the size of the Board by one director to a total of nine directors. Mr. Roberts will serve until the Company’s 2022 Annual Meeting of Stockholders or until his successor is duly elected or appointed or his earlier death or resignation. As a director of the Company, Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, described in the section entitled “Director Compensation” in our Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on April 29, 2022, but he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as a Partner of the Preferred Stock Investor.

Licensed rights and other intangible assets

9 Months Ended

Sep. 30, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Licensed rights and other intangible assets

6.	Licensed rights and other intangible assets

The following provides information about our license rights and other intangible assets, net (in thousands):

	September 30, 2022						December 31, 2021
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Licensed rights and intangible assets subject to amortization:
License rights	$	40,000	$	9,086	$	30,914	$	40,000	$	6,826	$	33,174
Hormone therapy drug patents		6,189		1,484		4,705		5,834		1,042		4,792
Hormone therapy drug patents applied and pending approval		1,936		—		1,936		2,020		—		2,020
License rights and other intangible assets subject to amortization		48,125		10,570		37,555		47,854		7,868		39,986
Intangible assets not subject to amortization:
Trademarks/trade name rights		321		—		321		332		—		332
License rights and other intangible assets, net	$	48,446	$	10,570	$	37,876	$	48,186	$	7,868	$	40,318

We recorded amortization expense related to the exclusive license rights agreement with Population Council of $0.8 million for the three months ended September 30, 2022 and 2021, and $2.3 million for the nine months ended September 30, 2022 and 2021. We recorded amortization expense related to patents of $0.1 million for the three months ended September 30, 2022 and 2021, and $0.4 million and $0.2 million for the nine months ended September 30, 2022 and 2021, respectively.

Business Concentrations (Tables)

9 Months Ended

Sep. 30, 2022

Disclosure of Revenue and Purchases [Line Items]

Summary of Customers with Product Revenue and Accounts Receivable

Customers with product revenue equal to or greater than 10% of our total revenue for the periods indicated were as follows:

	Nine Months Ended September 30,
	2022	2021
Customer A	*	10%
Customer B	18%	16%
Customer C	17%	18%
Customer E	*	12%
Customer F	16%	*
* Less than 10% of total product revenue

Summary of Vendors with Product Purchases and Accounts Payable

Vendors with product purchases equal to or greater than 10% of our total purchases for the periods indicated were as follows:

	Nine Months Ended September 30,
	2022	2021
Catalent	23%	27%
Vendor A	49%	41%
Vendor B	25%	30%
* Less than 10% of total product purchases

Accounts Receivable [Member]

Disclosure of Revenue and Purchases [Line Items]

Summary of Customers with Product Revenue and Accounts Receivable

Customers that accounted for 10% or greater of our accounts receivable as of the periods indicated were as follows:

	September 30, 2022	December 31, 2021
Customer B	27%	21%
Customer C	19%	35%
Customer D	10%	11%
Customer G	20%	*
* Balance was less than 10% of accounts receivable, gross

Accounts Payable [Member]

Disclosure of Revenue and Purchases [Line Items]

Summary of Vendors with Product Purchases and Accounts Payable

Vendors that accounted for 10% or greater of our accounts payable as of the periods indicated were as follows:

	September 30, 2022	December 31, 2021
Vendor E	*	19%
Vendor F	32%	20%
* Balance was less than 10% of total accounts payable

Accounts receivable (Tables)

9 Months Ended

Sep. 30, 2022

Receivables [Abstract]

Summary of accounts receivable allowance for credit losses

The following sets forth activities in our allowance for credit losses (in thousands):

Balance as of January 1, 2022	$	1,334
Charges to provision for credit losses		542
Write-off of uncollectible receivables		(255	)
Balance as of September 30, 2022	$	1,621

Prepaid and other current assets (Tables)

9 Months Ended

Sep. 30, 2022

Prepaid Expense And Other Assets Current [Abstract]

Schedule of prepaid and other current assets

Our prepaid and other current assets consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Insurance	$	2,370	$	2,731
Paragraph IV legal proceeding costs		2,334		2,304
Other		5,586		5,513
Prepaid and other current assets	$	10,290	$	10,548

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Schedule of Performance Stock Units (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

9 Months Ended

Sep. 30, 2022

Dec. 31, 2021

PSUs Outstanding [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Beginning balance, number of shares

164

Granted, number of shares

Vested and settled, number of shares

(52)

Forfeited, number of shares

(75)

Ending balance, number of shares

^[1]

100

Beginning balance, weighted average grant date fair value

$ 51.50

Granted, weighted average grant date fair value

34.50

Vested/Released, weighted average grant date fair value

58.26

Forfeited, weighted average grant date fair value

44.82

Ending balance, weighted average grant date fair value

$ 42.32

Aggregate intrinsic value

$ 664

$ 2,953

Aggregate intrinsic value, vested/released

$ 695

PSUs Vested and Not Settled [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Beginning balance, number of shares

Ending balance, number of shares

Beginning balance, weighted average grant date fair value

$ 58.81

Aggregate intrinsic value

$ 282

$ 709

[1]	^{The number of PSUs represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and 165,548 depending on the Company’s achievement of certain performance goals.}

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Schedule of Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
RSU Outstanding [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance, number of shares	272
Granted, number of shares	170
Vested/Released, number of shares	(106)
Forfeited, number of shares	(35)
Ending balance, number of shares	301
Beginning balance, weighted average grant date fair value	$ 58.93
Granted, weighted average grant date fair value	16.05
Vested/Released, weighted average grant date fair value	69.42
Forfeited, weighted average grant date fair value	54.91
Ending balance, weighted average grant date fair value	$ 31.50
Aggregate intrinsic value	$ 1,998	$ 4,891
Aggregate intrinsic value, vested/released	$ 1,180
RSU Vested and Not Settled [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance, number of shares	31
Ending balance, number of shares	104
Beginning balance, weighted average grant date fair value	$ 105.28
Ending balance, weighted average grant date fair value	$ 38.58
Aggregate intrinsic value	$ 692	$ 566

Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of presentation

A.	Basis of presentation

Common stock reverse stock split

New accounting standards

B.	New accounting standards

Adoption of new accounting standards

Accounting standards issued but not yet adopted

Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements or processes.

Estimates and assumptions

C.	Estimates and assumptions

Significant accounting policies

D.	Significant accounting policies

Restricted Cash

Restricted cash is comprised of escrowed funds deposited with a bank relating to the vitaCare Divestiture.

Reclassification of Prior Year Presentation

E.	Reclassification of prior year presentation

Related parties - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Catalent [Member]
Related Party Transaction [Line Items]
Amount billed	$ 1.1	$ 2.6

Earnings (loss) per common share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Earnings (loss) per common share

13.	Earnings (loss) per common share

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022		2021
Numerator:
Net income (loss)	$	(28,965	)	$	(47,420	)	$	34,295	$	(129,455	)
Denominator:
Weighted average common shares for basic loss per common share		9,261			8,444			8,877		7,762
Effect of dilutive securities		—			—			328		—
Weighted average common shares for diluted loss per common share		9,261			8,444			9,205		7,762
Earnings (loss) per common share, basic	$	(3.13	)	$	(5.62	)	$	3.86	$	(16.68	)
Earnings (loss) per common share, diluted	$	(3.13	)	$	(5.62	)	$	3.73	$	(16.68	)

Since we reported a net loss for the three months ended September 30, 2022, and for three and nine months ended September 30, 2021, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per common share and our basic and diluted weighted average common shares are the same for the three months ended September 30, 2022 and for the three and nine months ended September 30, 2021. There were 58 thousand of outstanding PSUs as of September 30, 2022 that were not potentially dilutive securities for the nine months ended September 30, 2022 because their performance requirements have not been met.

	As of September 30,
	2022		2021
Stock options		197		369
RSUs		301		323
PSUs		100		194
Warrants		411		103
		1,009		989

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Warrants - Additional Information (Details)		9 Months Ended
	May 06, 2022	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares
Class Of Stock [Line Items]
Reverse stock split, conversion ratio	0.02	0.02
Reverse stock split, description	outstanding shares of our Common Stock were split at a ratio of 50-for-1	50-for-1 reverse stock split
Warrant [Member]
Class Of Stock [Line Items]
Reverse stock split, conversion ratio		0.02
Reverse stock split, description		50-for-1 reverse stock split
Exercise price of common stock		$ 17.08	$ 76.19
Warrant [Member] \| July and September Lender Subscription Agreement [Member]
Class Of Stock [Line Items]
Class of Warrant or An aggregate of lenders warrants to purchase shares \| shares		310,000
Exercise price of common stock		$ 0.01

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 27,080	$ 65,122
Restricted cash	11,250
Accounts receivable, net of allowance for credit losses of $1,621 and $1,334 as of September 30, 2022 and December 31, 2021, respectively	32,157	36,176
Inventory	6,701	7,622
Prepaid and other current assets	10,290	10,548
Total current assets	87,478	119,468
Fixed assets, net	551	1,199
License rights and other intangible assets, net	37,876	40,318
Right of use assets	7,749	8,234
Other non-current assets	253	253
Total assets	133,907	169,472
Current liabilities:
Debt, net	93,602	188,269
Lender Warrants derivative liability	2,058
Make-whole payment derivative liability	1,751
Mandatory Redeemable Preferred Stock	19,709
Accounts payable	13,383	20,318
Accrued expenses and other current liabilities	43,568	44,304
Total current liabilities	174,071	252,891
Operating lease liabilities	7,553	8,063
Other non-current liabilities	554	2,139
Total liabilities	182,178	263,093
Commitments and contingencies (Note 9)
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000 shares authorized, 22 issued and included in liabilities due to their redemption provisions
Common stock, par value $0.001; 12,000 shares authorized, 9,467 and 8,598 (adjusted for the 50-for-1 reverse stock split) shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	9	9
Additional paid-in capital	968,785	957,730
Accumulated deficit	(1,017,065)	(1,051,360)
Total stockholders' deficit	(48,271)	(93,621)
Total liabilities and stockholders' deficit	$ 133,907	$ 169,472

Debt

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Debt

Our debt consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Financing Agreement	$	94,432	$	200,000
Less: deferred financing fees		830		11,731
Debt, net	$	93,602	$	188,269

Financing agreement

As of September 30, 2022, the stated interest rate under the Financing Agreement was 10.45%. In March 2022, we entered into Amendment No. 9 to the Financing Agreement (“Amendment No. 9”) pursuant to which, among other amendments, (i) the lenders

waived various Company breaches of the Financing Agreement, including breaches of the $60.0 million minimum cash covenant and the minimum net revenue covenants for the fourth quarter of 2021; (ii) the Company and the lenders agreed to a reduced minimum cash covenant and to the removal of the minimum net revenue covenant for the first quarter of 2022; (iii) the lenders waived the existing $60.0 million prepayment penalty under the Financing Agreement and the Company agreed to pay a paid in kind (“PIK”) amendment financing fee of $30.0 million, which fee was added to the principal amount of the loans under the Financing Agreement, $16.0 million of which fee was waivable in certain conditions; (iv) the maturity date of the Financing Agreement was amended to June 1, 2022; and (v) the Company agreed to pay to the Lenders as a prepayment of the loans under the Financing Agreement the first $120.0 million of net proceeds from the vitaCare Divestiture and all net proceeds of the vitaCare Divestiture in excess of $135.0 million. Amendment No. 9 was accounted for as an extinguishment of debt modification in accordance with U.S. GAAP. Accordingly, in March 2022, we recorded an $8.4 million loss on extinguishment of debt, which represented the unamortized deferred financing fees, net of previously accrued prepayment fees. Additionally, the Amendment No. 9 PIK financing fee was recorded as deferred financing fees and was amortized over the remaining term of the Financing Agreement. In April 2022, we utilized $120.0 million of net proceeds from the vitaCare Divestiture to make a prepayment of the loans under the Financing Agreement under the terms of Amendment No. 9. Additionally, with the prepayment on the debt, $16.0 million of the PIK financing fee was waived in accordance with Amendment No. 9.

In May 2022, we entered into Amendment No. 10 to the Financing Agreement (“Amendment No. 10”) pursuant to which, among other amendments, (i) interest payments under the Financing Agreement were paused, such that interest on each term loan shall be payable in cash and in arrears (a) upon any prepayment of that term loan, whether voluntary or mandatory, to the extent accrued on the amount being prepaid and (b) on the maturity date, (ii) the minimum cash covenant was set at $10.0 million, (iii) the maturity date of the Financing Agreement was amended to July 13, 2022, (iv) the termination of the Company’s merger agreement with an affiliate of EW Healthcare Partners was added as an event of default, and (v) we agreed to a PIK financing fee of $1.8 million, which fee was added to the principal amount of the loans under the Financing Agreement. Amendment No. 10 was accounted for as a debt amendment in accordance with U.S. GAAP. Accordingly, in May 2022, the Amendment No. 10 PIK financing fee was recorded as deferred financing fees and was amortized over the remaining term of the Financing Agreement.

Also in May 2022, we entered into Amendment No. 11 (“Amendment No. 11”) to the Financing Agreement. Amendment No. 11 contains amendments to the Financing Agreement that would have gone into effect upon the satisfaction of certain conditions on or before July 13, 2022 (the “Amendment Effective Date”), including (i) the consummation of the merger with an affiliate of EW Healthcare Partners (the “Merger”), (ii) the payment in cash of (a) all accrued and unpaid interest under the Financing Agreement through and including the Amendment Effective Date and (b) all fees, costs, expenses and taxes then payable pursuant to Section 2.7 or 10.2 of the Financing Agreement, and (iii) the delivery to the administrative agent of certain customary documents with respect to the pledge of 100% of the capital stock of the Company. Since the consummation of the Merger did not occur, Amendment No. 11 never became effective.

On July 13, 2022, we entered into Amendment No. 12 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to July 24, 2022, and we agreed to pay the Lenders a PIK amendment fee in the amount of $1.2 million. On July 24, 2022, we entered into Amendment No. 13 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to July 27, 2022, we agreed to pay the Lenders a payment of accrued and unpaid interest of $2.9 million, and we agreed to retain Jeffrey Varsalone from G2 Capital Advisors as our chief restructuring officer. On July 27, 2022, we entered into Amendment No. 14 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to July 28, 2022. On July 28, 2022, we entered into Amendment No. 15 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to July 29, 2022.

On July 29, 2022, we entered into Amendment No. 16 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to September 30, 2022, with the option for us to further extend the maturity date to October 31, 2022, and November 30, 2022, in each case if we receive not less than $7.0 million in cash proceeds from an equity issuance, which, if preferred equity, is on substantially the same terms as the Preferred Stock. In lieu of a cash amendment fee, to induce the Lenders to enter into Amendment No. 16, on July 29, 2022, we issued Lender Warrants to purchase an aggregate of 185,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “July Lender Subscription Agreement”). The Lender Warrants to purchase 185,000 shares of our Common Stock issued pursuant to the July Lender Subscription Agreement have an exercise price of $0.01 per warrant, subject to certain adjustment as provided therein, and an expiration date of July 29, 2032, and may be exercised via cashless exercise pursuant to the terms thereof. These Lender Warrants were initially valued at $1.2 million based on the market price of our Common Stock on July 29, 2022 and entirely expensed as financing costs during three and nine months ended September 30, 2022.

In connection with the closing of a private placement offering with the Preferred Stock Investor on September 30, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on September 30, 2022, we issued Lender Warrants to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “September Lender Subscription Agreement”), and the maturity date of the Financing Agreement was extended to October 31, 2022.

Subsequent to September 30, 2022, the maturity date was extended to November 30, 2022 in connection with an additional private placement, See Note 16, Subsequent Events. The Lender Warrants to purchase 125,000 shares of our Common Stock issued pursuant to

the September Lender Subscriptions Agreement have an exercise price of $0.01 per warrant, subject to certain adjustment as provided therein, and an expiration date of September 30, 2032, and may be exercised via cashless exercise pursuant to the terms thereof. See Note 10, Mandatory Redeemable Preferred Stock and Stockholders’ Deficit for additional information regarding the equity financing with the Preferred Stock Investor. These Lender Warrants were initially valued at $0.8 million based on the market price of our Common Stock on September 30, 2022 and recorded as deferred financing fees, which will be amortized until the maturity of the Financing Agreement.

Based on the structure of the Lender Warrants, they are recorded as Lender Warrants derivative liability in the consolidated balance sheets and their carrying amounts are marked to market based on our Common Stock’s closing price at measurement date, which is considered Level 1 under the fair value hierarchy. As of September 30, 2022, the fair value of our Lender Warrants derivative liability was $2.1 million, and we recorded fair value loss on the Lender Warrants derivative liability of $0.1 million for three and nine months ended September 30, 2022.

Additionally, in September 2022, we and the Lenders agreed to PIK interest of $2.5 million related to the outstanding debt balance, which was entirely expensed as interest expense during three and nine months ended September 30, 2022.

Debt covenants

The Financing Agreement contains customary restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to maintain a minimum unrestricted cash balance. As defined in Amendment No. 10, the minimum unrestricted cash balance was set at $10.0 million. Our unrestricted cash balance was above the minimum unrestricted cash balance covenant at all times through November 14, 2022, the filing date of this 10-Q Report.

Interest and financing costs

Interest expense and other financing costs consisted of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Interest expense	$	2,251	$	5,391	$	10,888	$	17,175
Interest prepayment fees		—		650		—		4,008
Financing fees amortization		2,582		1,477		20,053		4,158
Interest expense and other financing costs	$	4,833	$	7,518	$	30,941	$	25,341

Revenue - Summary of information about disaggregated revenue by product mix (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Product revenue:
Total revenue, net	$ 20,917	$ 25,406	$ 68,811	$ 68,273
ANNOVERA [Member]
Product revenue:
Total revenue, net	10,415	11,807	37,196	30,112
IMVEXXY [Member]
Product revenue:
Total revenue, net	6,947	8,016	20,583	24,866
BIJUVA [Member]
Product revenue:
Total revenue, net	2,663	3,298	7,877	7,899
Prescription Vitamins [Member]
Product revenue:
Total revenue, net	892	1,335	2,671	4,162
Product [Member]
Product revenue:
Total revenue, net	$ 20,917	24,456	68,327	67,039
License and Service [Member]
Product revenue:
Total revenue, net		$ 950	$ 484	$ 1,234

- Definition

+ References

+ Details

Subsequent events

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Subsequent events

16.	Subsequent events

On October 28, 2022, we entered into a Subscription Agreement with the Preferred Stock Investor, pursuant to which the Company issued and sold, in a private placement offering, 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of the Company’s Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the Preferred Stock Maturity Date or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment. This offering closed on October 28, 2022, and we received gross proceeds of $7.0 million, before expenses.

In connection with the closing of the private placement offering with the Preferred Stock Investor on October 28, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on October 28, 2022, we issued Lender Warrants to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders, and the maturity date of the Financing Agreement was extended to November 30, 2022. These Lender Warrants have an exercise price of $0.01 per share of Common Stock, subject to certain adjustment as provided therein, and an expiration date of October 28, 2032.

Business concentrations - Summary of Customers with Product Revenue (Details) - Customer Concentration Risk [Member] - Revenue [Member]	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Customer A [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage		10.00%
Customer B [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	18.00%	16.00%
Customer C [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	17.00%	18.00%
Customer E [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage		12.00%
Customer F [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	16.00%

Earnings (loss) per common share - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,009	989		989
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	197	369		369
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	301	323		323
PSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100	194	58	194
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	411	103		103

Mandatory Redeemable Preferred Stock and Stockholders' Deficit - Summary of Unrecognized Share Based Compensation Cost Expected to be Recognized (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Equity [Abstract]
2022 (3 months)	$ 1,098
2023	3,255
2024	1,556
2025	157
Total	$ 6,066

Mandatory Redeemable Preferred Stock and Stockholders' Deficit) - Summary of Stock Option Activity (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Options awards outstanding, Beginning balance	353
Options awards outstanding, Cancelled/Forfeited	(1)
Options awards outstanding, Expired	(155)
Options awards outstanding, Ending balance	197	353
Options awards outstanding, weighted average exercise price, Beginning balance	$ 225.98
Options awards outstanding, weighted average exercise price, Cancelled/Forfeited	1,885.39
Options awards outstanding, weighted average exercise price, Expired	238.45
Options awards outstanding, weighted average exercise price, Ending balance	$ 216.65	$ 225.98
Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)	3 years 6 months	3 years 9 months 18 days
Options awards exercisable, Option Awards	336
Options awards exercisable, Option Awards	192	336
Options awards exercisable, Weighted Average Exercise Price	$ 219.65	$ 230.93
Options awards exercisable, Weighted Average Remaining Contractual Life (in Years)	3 years 4 months 24 days	3 years 7 months 6 days

Licensed rights and other intangible assets (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Information about License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net (in thousands):

	September 30, 2022						December 31, 2021
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Licensed rights and intangible assets subject to amortization:
License rights	$	40,000	$	9,086	$	30,914	$	40,000	$	6,826	$	33,174
Hormone therapy drug patents		6,189		1,484		4,705		5,834		1,042		4,792
Hormone therapy drug patents applied and pending approval		1,936		—		1,936		2,020		—		2,020
License rights and other intangible assets subject to amortization		48,125		10,570		37,555		47,854		7,868		39,986
Intangible assets not subject to amortization:
Trademarks/trade name rights		321		—		321		332		—		332
License rights and other intangible assets, net	$	48,446	$	10,570	$	37,876	$	48,186	$	7,868	$	40,318

Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,946	$ 3,042
Work in process	218	1,642
Finished products	4,537	2,938
Inventory	$ 6,701	$ 7,622

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Nov. 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-00100
Entity Registrant Name	THERAPEUTICSMD, INC.
Entity Central Index Key	0000025743
Entity Tax Identification Number	87-0233535
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	951 Yamato Road
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	961-1900
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TXMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,467,104

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue, net	$ 20,917,000	$ 25,406,000	$ 68,811,000	$ 68,273,000
Cost of goods sold	3,788,000	5,282,000	13,388,000	14,101,000
Total gross profit	17,129,000	20,124,000	55,423,000	54,172,000
Operating expenses:
Selling and marketing	19,129,000	30,005,000	61,703,000	86,193,000
General and administrative	17,635,000	28,435,000	55,445,000	66,691,000
Research and development	1,112,000	1,605,000	4,092,000	5,666,000
Total operating expenses	37,876,000	60,045,000	121,240,000	158,550,000
Loss from operations	(20,747,000)	(39,921,000)	(65,817,000)	(104,378,000)
Other (expense) income:
Gain on sale of business			143,384,000
Expense for accretion of Mandatory Redeemable Preferred Stock	(3,457,000)		(3,457,000)
Fair value loss on Lender Warrants derivative liability	(76,000)		(76,000)
Loss on extinguishment of debt			(8,380,000)
Interest expense and other financing costs	(4,833,000)	(7,518,000)	(30,941,000)	(25,341,000)
Other (expense) income, net	(112,000)	19,000	(128,000)	264,000
Total other (expense) income, net	(8,478,000)	(7,499,000)	100,402,000	(25,077,000)
(Loss) income before income taxes	(29,225,000)	(47,420,000)	34,585,000	(129,455,000)
(Benefit) provision for income taxes	(260,000)	0	290,000	0
Net (loss) income	$ (28,965,000)	$ (47,420,000)	$ 34,295,000	$ (129,455,000)
(Loss) earnings per common share, basic	$ (3.13)	$ (5.62)	$ 3.86	$ (16.68)
Weighted average common shares, basic	9,261	8,444	8,877	7,762
(Loss) earnings per common share, diluted	$ (3.13)	$ (5.62)	$ 3.73	$ (16.68)
Weighted average common shares, diluted	9,261	8,444	9,205	7,762
Comprehensive (loss) income:
Net (loss) income	$ (28,965,000)	$ (47,420,000)	$ 34,295,000	$ (129,455,000)
Comprehensive (loss) income	(28,965,000)	(47,420,000)	34,295,000	(129,455,000)
Product [Member]
Total revenue, net	$ 20,917,000	24,456,000	68,327,000	67,039,000
License and Service [Member]
Total revenue, net		$ 950,000	$ 484,000	$ 1,234,000

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
Inventory - Additional Information (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory charge	$ 0	$ 600,000	$ 73,000	$ 1,082,000

Prepaid and other current assets

9 Months Ended

Sep. 30, 2022

Prepaid Expense And Other Assets Current [Abstract]

Prepaid and other current assets

4.	Prepaid and other current assets

Our prepaid and other current assets consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Insurance	$	2,370	$	2,731
Paragraph IV legal proceeding costs		2,334		2,304
Other		5,586		5,513
Prepaid and other current assets	$	10,290	$	10,548

Inventory

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Inventory

Our inventory consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Raw materials	$	1,946	$	3,042
Work in process		218		1,642
Finished products		4,537		2,938
Inventory	$	6,701	$	7,622

We recorded no inventory charges for the three months ended September 30, 2022 and $0.1 million for the nine months ended September 30, 2022, and $0.6 million and $1.1 million for the three and nine months ended September 30, 2021, respectively.

We rely on third parties to manufacture our finished products, and we have entered into long-term supply agreements for the manufacture of ANNOVERA, IMVEXXY, and BIJUVA. We do not have a long-term supply agreement for the manufacture of our prescription vitamins. Additionally, we do not have long-term contracts for the supply of all the active pharmaceutical ingredients (“API”) used in ANNOVERA and BIJUVA. If any suppliers of raw materials or API or any of our third-party contract manufacturers experience any difficulties, do not comply with the terms of an agreement between us, or do not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience additional interruptions in the supply of our products, which may have a material adverse impact on our revenue, results of operations and financial position.

Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands							1 Months Ended			3 Months Ended	9 Months Ended
	Oct. 28, 2022	Jul. 29, 2022	Jul. 28, 2022	Jul. 27, 2022	Jul. 24, 2022	Jul. 13, 2022	May 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Prepayment of debt											$ 125,000	$ 50,000
Loss on extinguishment of debt											8,380
Deferred financing fees										$ 830	830		$ 11,731
Warrants derivative liability										2,100	2,100
Loss on warrants derivative liability										100	100
Payment in kind interest										$ 2,500	$ 2,500
Financing Agreement [Member]
Debt Instrument [Line Items]
Stated interest rate										10.45%	10.45%
Financing Agreement Amendment No 9 [Member]
Debt Instrument [Line Items]
Minimum cash balance requirement under credit agreements									$ 60,000
Prepayment penalty									60,000
Payment of in kind amendment financing fee									30,000
Loss on extinguishment of debt									8,400
Financing Agreement Amendment No 10 [Member]
Debt Instrument [Line Items]
Minimum cash balance requirement under credit agreements							$ 10,000
Payment of in kind amendment financing fee							$ 1,800
Maturity date							Jul. 13, 2022
Financing Agreement Amendment No 11 [Member]
Debt Instrument [Line Items]
Percentage of capital stock pledged							100.00%
Financing Agreement Amendment No 12 [Member]
Debt Instrument [Line Items]
Maturity date						Jul. 24, 2022
Payment in kind amendment fee payable to lender						$ 1,200
Financing Agreement Amendment No 13 [Member]
Debt Instrument [Line Items]
Maturity date					Jul. 27, 2022
Accrued and unpaid interest payable to lenders					$ 2,900
Financing Agreement Amendment No 14 [Member]
Debt Instrument [Line Items]
Maturity date				Jul. 28, 2022
Financing Agreement Amendment No 15 [Member]
Debt Instrument [Line Items]
Maturity date			Jul. 29, 2022
Financing Agreement Amendment No 16 [Member]
Debt Instrument [Line Items]
Warrants issued to purchase of common stock		185,000								125,000	125,000
Exercise price of common stock		$ 0.01								$ 0.01	$ 0.01
Warrants issued to purchase price of common stock		$ 1,200								$ 800	$ 800
Financing Agreement Amendment No 16 [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Maturity date	Nov. 30, 2022
Warrants issued to purchase of common stock	125,000
Exercise price of common stock	$ 0.01
Financing Agreement Amendment No 16 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Threshold value of cash proceeds from equity issuance		$ 7,000
Debt Covenants [Member] \| Financing Agreement Amendment No 9 [Member]
Debt Instrument [Line Items]
Waivable in kind amendment fee									16,000
Prepayment of debt									120,000
Waived in kind amendment fee								$ 16,000
Debt Covenants [Member] \| Financing Agreement Amendment No 9 [Member] \| VitaCare Divestiture [Member]
Debt Instrument [Line Items]
Prepayment of debt								$ 120,000
Debt Covenants [Member] \| Financing Agreement Amendment No 9 [Member] \| Minimum [Member] \| VitaCare Divestiture [Member]
Debt Instrument [Line Items]
Proceeds from divestiture of business to pay off debt, threshold amount									$ 135,000
Debt Covenants [Member] \| Financing Agreement Amendment No 10 [Member]
Debt Instrument [Line Items]
Minimum cash balance requirement under credit agreements										$ 10,000	$ 10,000

Income Taxes

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

12.	Income taxes

We do not expect to pay any significant federal income taxes as a result of (i) losses expected for the remainder of 2022 or losses recorded in 2021, or (ii) net operating losses carry forwards from prior years.

For the three and nine months ended September 30, 2022, we recorded a benefit and a provision for income taxes of $0.3 million, respectively, due to limitation of using net operating losses carry forwards in certain states. For the three and nine months ended September 30, 2021, no provision or benefits for income taxes were recorded since we recorded net losses and full valuation allowance for such periods. As of September 30, 2022 and December 31, 2021, we maintain a full valuation allowance for all deferred tax assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Fixed assets - Summary of Fixed Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Fixed assets	$ 3,547	$ 3,717
Less: accumulated depreciation and amortization	2,996	2,518
Fixed assets, net	551	1,199
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Fixed assets	1,304	1,407
Computer and office equipment [Member]
Property Plant And Equipment [Line Items]
Fixed assets	1,803	1,855
Computer software [Member]
Property Plant And Equipment [Line Items]
Fixed assets	375	375
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Fixed assets	$ 65	$ 80

Accrued expenses and other current liabilities

9 Months Ended

Sep. 30, 2022

Payables And Accruals [Abstract]

Accrued expenses and other current liabilities

7.	Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Payroll and related costs	$	8,460	$	13,764
Rebates		16,854		11,010
Sales returns and coupons		3,434		2,422
Selling and marketing		3,475		2,850
Research and development expenses		1,826		1,995
Wholesale distributor fees		4,520		3,614
Professional fees		739		2,571
Operating lease liabilities		1,383		1,361
Income taxes payable		290		—
Other accrued expenses and current liabilities		2,587		4,717
Accrued expenses and other current liabilities	$	43,568	$	44,304

We expense advertising costs when incurred, which amounted to $4.8 million and $14.6 million for the three months ended September 30, 2022 and 2021, respectively, and $12.6 million and $34.4 million for the nine months ended September 30, 2022 and 2021, respectively.

Accounts receivable

9 Months Ended

Sep. 30, 2022

Receivables [Abstract]

Accounts receivable

2.	Accounts receivable

The following sets forth activities in our allowance for credit losses (in thousands):

Balance as of January 1, 2022	$	1,334
Charges to provision for credit losses		542
Write-off of uncollectible receivables		(255	)
Balance as of September 30, 2022	$	1,621

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 34,295,000	$ (129,455,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	3,181,000	3,091,000
Charges to provision for doubtful accounts	542,000	540,000
Inventory charge	73,000	1,082,000
Debt financing fees	20,053,000	4,158,000
Share-based compensation	8,587,000	12,779,000
Gain on sale of business	(143,384,000)
Expense for accretion of Mandatory Redeemable Preferred Stock	3,457,000
Loss on extinguishment of debt	8,380,000
Other	50,000	726,000
Changes in operating assets and liabilities:
Accounts receivable	3,044,000	(5,560,000)
Inventory	848,000	(451,000)
Prepaid and other current assets	180,000	(2,831,000)
Accounts payable	(6,186,000)	(1,476,000)
Accrued expenses and other current liabilities	3,705,000	13,504,000
Other non-current liabilities	(675,000)	758,000
Total adjustments	(98,145,000)	26,320,000
Net cash used in operating activities	(63,850,000)	(103,135,000)
Cash flows from investing activities:
Proceeds from sale of business, net of transaction costs	142,634,000
Payment of patent related costs	(297,000)	(675,000)
Purchase of fixed assets	(21,000)	(34,000)
Net cash provided by (used in) investing activities	142,316,000	(709,000)
Cash flows from financing activities:
Proceeds from sale of Mandatory Redeemable Preferred Stock, net of costs	16,252,000
Proceeds from make-whole derivative	1,751,000
Proceeds from sale of common stock, net of costs	2,454,000	182,881,000
Proceeds from exercise of options and warrants		302,000
Proceeds from sale of common stock related to employee stock purchase plan	14,000	134,000
Repayments of debt	(125,000,000)	(50,000,000)
Payment of debt financing fees	(729,000)	(5,118,000)
Net cash (used in) provided by financing activities	(105,258,000)	128,199,000
Net (decrease) increase in cash and restricted cash	(26,792,000)	24,355,000
Cash and restricted cash, beginning of period	65,122,000	80,486,000
Cash and restricted cash, end of period	38,330,000	104,841,000
Supplemental disclosure of cash flow information:
Interest paid	8,371,000	$ 19,675,000
Supplemental disclosure of noncash financing activities:
Paid in kind ("PIK") interest with corresponding increase in debt	2,452,000
PIK debt financing fees with corresponding increase in debt	16,980,000
Issue of warrants to lenders related to debt financing fees	$ 1,983,000

Fixed assets

9 Months Ended

Sep. 30, 2022

Property Plant And Equipment [Abstract]

Fixed assets

5.	Fixed assets

Our fixed assets, net consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Furniture and fixtures	$	1,304	$	1,407
Computer and office equipment		1,803		1,855
Computer software		375		375
Leasehold improvements		65		80
Fixed assets		3,547		3,717
Less: accumulated depreciation and amortization		2,996		2,518
Fixed assets, net	$	551	$	1,199

We recorded depreciation expense of $0.2 million for the three months ended September 30, 2022 and 2021, and $0.5 million and $0.6 million for the nine months ended September 30, 2022 and 2021, respectively.

Revenue

9 Months Ended

Sep. 30, 2022

Disaggregation Of Revenue [Abstract]

Revenue

11.

Revenue

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Product revenue:
ANNOVERA	$	10,415	$	11,807	$	37,196	$	30,112
IMVEXXY		6,947		8,016		20,583		24,866
BIJUVA		2,663		3,298		7,877		7,899
Prescription vitamin		892		1,335		2,671		4,162
Product revenue, net		20,917		24,456		68,327		67,039
License and service		-		950		484		1,234
Total revenue, net	$	20,917	$	25,406	$	68,811	$	68,273

We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. We also have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY and BIJUVA for human use outside of the U.S., except for Canada and Israel.

We recorded BIJUVA sales through the Theramex License Agreement of $0.4 million and $1.4 million for the three and nine months ended September 30, 2022, respectively, and $0.7 million for the three and nine months ended September 30, 2021. For the three and nine months ended three and nine months ended September 30, 2022 and 2021, no BIJUVA sales have been made through the Knight License Agreement.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
(Benefit) provision for income taxes	$ (260,000)	$ 0	$ 290,000	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Business concentrations - Summary of Customers that Accounted for 10% or Greater of Accounts Receivable (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Customer B [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	27.00%	21.00%
Customer C [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	19.00%	35.00%
Customer G [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	20.00%
Customer D [Member]
Disclosure Of Customers With Product Revenue and Account Receivable For The Period [Line Items]
Concentration Risk, Percentage	10.00%	11.00%

Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Disaggregation Of Revenue [Abstract]

Summary of information about disaggregated revenue by product mix

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Product revenue:
ANNOVERA	$	10,415	$	11,807	$	37,196	$	30,112
IMVEXXY		6,947		8,016		20,583		24,866
BIJUVA		2,663		3,298		7,877		7,899
Prescription vitamin		892		1,335		2,671		4,162
Product revenue, net		20,917		24,456		68,327		67,039
License and service		-		950		484		1,234
Total revenue, net	$	20,917	$	25,406	$	68,811	$	68,273

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance, value at Dec. 31, 2020	$ (124,001)	$ 6	$ 754,938	$ (878,945)
Beginning balance, shares at Dec. 31, 2020		5,996,000
Sale of common stock, net of costs	150,899	$ 2	150,897
Shares issued for sale of common stock, net of cost, shares		1,857,000
Exercise of warrants, net of cashless exercises	50		50
Shares issued for exercise of warrants and options, net of cashless exercises (in shares)		10,000
Vested restricted stock units		1,000
Share-based compensation	2,957		2,957
Net income (loss)	(39,383)			(39,383)
Ending balance, value at Mar. 31, 2021	(9,478)	$ 8	908,842	(918,328)
Ending balance, shares at Mar. 31, 2021		7,864,000
Beginning balance, value at Dec. 31, 2020	(124,001)	$ 6	754,938	(878,945)
Beginning balance, shares at Dec. 31, 2020		5,996,000
Net income (loss)	(129,455)
Ending balance, value at Sep. 30, 2021	(57,360)	$ 9	951,031	(1,008,400)
Ending balance, shares at Sep. 30, 2021		8,498,000
Beginning balance, value at Mar. 31, 2021	(9,478)	$ 8	908,842	(918,328)
Beginning balance, shares at Mar. 31, 2021		7,864,000
Sale of common stock, net of costs	163		163
Shares issued for sale of common stock, net of cost, shares		3,000
Exercise of warrants, net of cashless exercises	249		249
Shares issued for exercise of warrants and options, net of cashless exercises (in shares)		13,000
Vested restricted stock units		19,000
Sale of common stock related to employee stock purchase plan	134		134
Shares issued for sale of common stock related to employee stock purchase plan (in shares)		3,000
Share-based compensation	2,510		2,510
Net income (loss)	(42,652)			(42,652)
Ending balance, value at Jun. 30, 2021	(49,074)	$ 8	911,898	(960,980)
Ending balance, shares at Jun. 30, 2021		7,902,000
Sale of common stock, net of costs	31,819	$ 1	31,818
Shares issued for sale of common stock, net of cost, shares		575,000
Exercise of options	3		3
Vested restricted stock units		21,000
Share-based compensation	7,312		7,312
Net income (loss)	(47,420)			(47,420)
Ending balance, value at Sep. 30, 2021	(57,360)	$ 9	951,031	(1,008,400)
Ending balance, shares at Sep. 30, 2021		8,498,000
Beginning balance, value at Dec. 31, 2021	$ (93,621)	$ 9	957,730	(1,051,360)
Beginning balance, shares at Dec. 31, 2021	8,598,000	8,598,000
Vested restricted stock units		71,000
Share-based compensation	$ 2,062		2,062
Net income (loss)	(49,021)			(49,021)
Ending balance, value at Mar. 31, 2022	(140,580)	$ 9	959,792	(1,100,381)
Ending balance, shares at Mar. 31, 2022		8,669,000
Beginning balance, value at Dec. 31, 2021	$ (93,621)	$ 9	957,730	(1,051,360)
Beginning balance, shares at Dec. 31, 2021	8,598,000	8,598,000
Net income (loss)	$ 34,295
Ending balance, value at Sep. 30, 2022	$ (48,271)	$ 9	968,785	(1,017,065)
Ending balance, shares at Sep. 30, 2022	9,467,000	9,467,000
Beginning balance, value at Mar. 31, 2022	$ (140,580)	$ 9	959,792	(1,100,381)
Beginning balance, shares at Mar. 31, 2022		8,669,000
Shares issued for rounding up of fractional shares in connection with the reverse stock split (in shares)		142,000
Vested restricted stock units		44,000
Sale of common stock related to employee stock purchase plan	14		14
Shares issued for sale of common stock related to employee stock purchase plan (in shares)		5,000
Share-based compensation	2,219		2,219
Net income (loss)	112,281			112,281
Ending balance, value at Jun. 30, 2022	(26,066)	$ 9	962,025	(988,100)
Ending balance, shares at Jun. 30, 2022		8,860,000
Sale of common stock, net of costs	2,454		2,454
Shares issued for sale of common stock, net of cost, shares		565,000
Vested restricted stock units		42,000
Share-based compensation	4,306		4,306
Net income (loss)	(28,965)			(28,965)
Ending balance, value at Sep. 30, 2022	$ (48,271)	$ 9	$ 968,785	$ (1,017,065)
Ending balance, shares at Sep. 30, 2022	9,467,000	9,467,000

Business, basis of presentation, new accounting standards and summary of significant accounting policies - Additional Information (Details) $ / shares in Units, $ in Thousands						3 Months Ended				9 Months Ended
	Oct. 28, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Jul. 29, 2022 USD ($) $ / shares shares	May 06, 2022 shares	Apr. 14, 2022 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Jun. 30, 2021 USD ($) shares	Mar. 31, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	May 05, 2022 shares	Dec. 31, 2021 $ / shares shares
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of business, net of transaction costs										$ 142,634
Gain on sale of business										143,384
Restricted cash		$ 11,250				$ 11,250				11,250
Loss from operations						20,747	$ 39,921			65,817	$ 104,378
Interest expense and other financing costs						$ 4,833	7,518			30,941	$ 25,341
Current liabilities over current assets										86,600
Total liabilities over total assets										$ 48,300
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001			$ 0.001
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001			$ 0.001
Aggregate purchase price						$ 2,454	$ 31,819	$ 163	$ 150,899
Reverse stock split, conversion ratio				0.02						0.02
Reverse stock split, description				outstanding shares of our Common Stock were split at a ratio of 50-for-1						50-for-1 reverse stock split
Number of authorized shares of common stock \| shares		12,000,000		12,000,000.0		12,000,000				12,000,000		600,000,000.0	12,000,000
Common Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold \| shares						565,000	575,000	3,000	1,857,000
Aggregate purchase price							$ 1		$ 2
Subscription Agreement [Member] \| Rubric Capital Management LP [Member] \| Private Placement Offering [Member] \| Common Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold \| shares			565,000
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001
Aggregate purchase price			$ 2,700
Number of shares for make-whole payment under financing agreement \| shares		263,666
Subscription Agreement [Member] \| Rubric Capital Management LP [Member] \| Private Placement Offering [Member] \| Series A Preferred Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold \| shares		7,000	15,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001
Aggregate gross proceeds		$ 7,000	$ 15,000
Aggregate purchase price		$ 7,000	$ 12,300
Subscription Agreement [Member] \| Preferred Stock Investor [Member] \| Private Placement Offering [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of shares for make-whole payment under financing agreement \| shares			263,666
Subscription Agreement [Member] \| Preferred Stock Investor [Member] \| Private Placement Offering [Member] \| Subsequent Event [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of shares for make-whole payment under financing agreement \| shares	263,666
Subscription Agreement [Member] \| Preferred Stock Investor [Member] \| Private Placement Offering [Member] \| Preferred Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold \| shares			7,000
Aggregate purchase price			$ 7,000
Maturity date of preferred stock description			(i) the maturity date of the Preferred Stock of December 31, 2022, which shall be automatically extended, on a day-for-day basis, to the extent the maturity date under the Financing Agreement is extended, but by no more than a total of 60 days without the consent of the holders representing at least 66 2/3% of the outstanding shares of Preferred Stock (the “Preferred Stock Maturity Date”)
Maximum number of days for preferred stock maturity date extension			60 days
Percentage of minimum outstanding shares of preferred stock require to consent to extent maturity date			66.6666%
Subscription Agreement [Member] \| Preferred Stock Investor [Member] \| Private Placement Offering [Member] \| Preferred Stock [Member] \| Subsequent Event [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold \| shares	7,000
Aggregate gross proceeds	$ 7,000
Aggregate purchase price	$ 7,000
Financing Agreement Amendment No 16 [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warrants issued to purchase of common stock \| shares		125,000	185,000			125,000				125,000
Exercise price of common stock \| $ / shares		$ 0.01	$ 0.01			$ 0.01				$ 0.01
Financing Agreement Amendment No 16 [Member] \| Subsequent Event [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warrants issued to purchase of common stock \| shares	125,000
Exercise price of common stock \| $ / shares	$ 0.01
Financing Agreement Amendment No 16 [Member] \| Common Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warrants issued to purchase of common stock \| shares			125,000
Financing Agreement Amendment No 16 [Member] \| Maximum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Threshold value of cash proceeds from equity issuance			$ 7,000
VitaCare Divestiture [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of business, net of transaction costs					$ 142,600
Transaction costs					7,200
Gain on sale of business					143,400
Estimated minimum service fee commitment for remainder of fiscal year					2,000
Estimated minimum service fee commitment, due 2023					10,700
Estimated minimum service fee commitment, due 2024					13,400
Estimated minimum service fee commitment, due 2025					15,400
Estimated minimum service fee commitment, due 2026					16,200
Estimated minimum service fee commitment, due 2027					5,500
VitaCare Divestiture [Member] \| Maximum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Contingent cash consideration from sale of business					7,000
VitaCare Divestiture [Member] \| Purchase Agreement
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Restricted cash					$ 11,300